Watch SKYE. Know when insiders buy.
One email the day a filing lands. Free.
SKYE
Skye Bioscience, Inc.
1.60
−0.03 −1.84%
USD · close Oct 22
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
63
WATCH · insiders 26, shorts 100
Insiders, 90 days
−$887K
net selling · 0 buys, 22 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $56.7MP/E —DIV YIELD —FCF YIELD -68.48%REV TTM —NET INCOME −$50.5MNET CASH $8M52W 1.53 – 12.88SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$11.1M | −$10.8M | — | -0.27 | −$7.1M | $0 | −$7.1M | Aug 14 |
| Q1 2026 · Mar 31 | — | — | — | −$12.7M | −$12.5M | — | -0.32 | −$8.6M | $0 | −$8.6M | Aug 14 |
| Q4 2025 · Dec 31derived | — | — | — | −$14.9M | −$14.4M | — | -0.36 | −$9.8M | $0 | −$9.8M | Mar 10 |
| Q3 2025 · Sep 30 | — | — | — | −$13.3M | −$12.8M | — | -0.32 | −$13.4M | $0 | −$13.4M | Nov 10 |
| Q2 2025 · Jun 30 | — | — | — | −$18.2M | −$17.6M | — | -0.44 | −$10.7M | $0 | −$10.7M | Aug 14 |
| Q1 2025 · Mar 31 | — | — | — | −$11.8M | −$11.1M | — | -0.28 | −$9.2M | $6K | −$9.2M | Aug 14 |
| Q4 2024 · Dec 31derived | — | — | — | −$10.7M | −$9.7M | — | -0.25 | −$8.2M | $50K | −$8.2M | Mar 10 |
| Q3 2024 · Sep 30 | — | — | — | −$5M | −$3.9M | — | -0.10 | −$5.3M | $1.5M | −$6.8M | Nov 10 |
| Q2 2024 · Jun 30 | — | — | — | −$8.4M | −$7.9M | — | -0.20 | −$7.1M | $32K | −$7.1M | Nov 10 |
| Q1 2024 · Mar 31 | — | — | — | −$6.2M | −$5M | — | -0.18 | −$4.7M | $3K | −$4.7M | Nov 10 |
| Q4 2023 · Dec 31derived | — | — | — | −$4.1M | −$4.4M | — | 1.01 | −$3.8M | $7K | −$3.9M | Mar 20 |
| Q3 2023 · Sep 30 | — | — | — | −$24.7M | −$24.9M | — | -3.17 | −$4.1M | $4K | −$4.1M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$58.2M | −$55.9M | — | -1.41 | −$43.1M | $6K | −$43.1M | — | — |
| FY2024 · to Dec 31 | — | — | −$30.2M | −$26.6M | — | -0.73 | −$25.2M | $1.6M | −$26.8M | — | — |
| FY2023 · to Dec 31 | — | — | −$34.7M | −$37.6M | — | -5.37 | −$14M | $13K | −$14M | — | — |
| FY2022 · to Dec 31 | — | — | −$18.3M | −$19.5M | — | -8.77 | −$12.7M | $28K | −$12.8M | — | — |
| FY2021 · to Dec 31 | — | — | −$7.8M | −$8.5M | — | -0.02 | −$6.5M | $91K | −$6.6M | — | — |
| FY2020 · to Dec 31 | — | — | −$6.3M | −$6.6M | — | -0.03 | −$6.1M | $7K | −$6.1M | — | — |
Every number comes from Skye Bioscience, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.